The gains in the global fight against tuberculosis have been threatened as a result of the COVID-19 pandemic, including a diversion of resources that have led to disruptions in ongoing research and control programs.
In a general population of patients with latent TB infection (including patients with and without HIV), studies have confirmed the superior safety profile of treatment with rifampicin vs isoniazid.
Whole genome sequencing of M tuberculosis isolates can identify complete drug susceptibility profiles, allowing precise treatment in early TB infection.
For patients with XDR tuberculosis, the overall risk-benefit ratio seems to favor patients receiving the bedaquiline-pretomanid-linezolid regimen with linezolid at a dose of 600 mg for 26 weeks.
Researchers assessed the safety and effectiveness of twice-daily dolutegravir dosing plus rifampicin in children with HIV-associated tuberculosis infection.
Should clofazimine remain a “second-choice agent” for treating patients with multidrug-resistant tuberculosis? A meta-analysis reviews the current evidence.
New research re-examines the current concern that using moxifloxacin in the shorter regimen for drug-resistant TB might increase the risk for QT prolongation.
